Nurix Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $9.12
- Today's High:
- $9.5499
- Open Price:
- $9.31
- 52W Low:
- $8.12
- 52W High:
- $16.81
- Prev. Close:
- $9.32
- Volume:
- 212272
Company Statistics
- Market Cap.:
- $416.93 million
- Book Value:
- 5.457
- Revenue TTM:
- $60.94 million
- Operating Margin TTM:
- -270.98%
- Gross Profit TTM:
- $-145870000
- Profit Margin:
- -258.37%
- Return on Assets TTM:
- -27.71%
- Return on Equity TTM:
- -59.79%
Company Profile
Nurix Therapeutics Inc had its IPO on 2020-07-24 under the ticker symbol NRIX.
The company operates in the Healthcare sector and Biotechnology industry. Nurix Therapeutics Inc has a staff strength of 297 employees.
Stock update
Shares of Nurix Therapeutics Inc opened at $9.31 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $9.12 - $9.55, and closed at $9.15.
This is a -1.82% slip from the previous day's closing price.
A total volume of 212,272 shares were traded at the close of the day’s session.
In the last one week, shares of Nurix Therapeutics Inc have increased by +5.78%.
Nurix Therapeutics Inc's Key Ratios
Nurix Therapeutics Inc has a market cap of $416.93 million, indicating a price to book ratio of 1.7012 and a price to sales ratio of 14.3102.
In the last 12-months Nurix Therapeutics Inc’s revenue was $60.94 million with a gross profit of $-145870000 and an EBITDA of $-159600992. The EBITDA ratio measures Nurix Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Nurix Therapeutics Inc’s operating margin was -270.98% while its return on assets stood at -27.71% with a return of equity of -59.79%.
In Q1.6666666666667, Nurix Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 168.3%.
Nurix Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.97 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Nurix Therapeutics Inc’s profitability.
Nurix Therapeutics Inc stock is trading at a EV to sales ratio of 6.4095 and a EV to EBITDA ratio of -1.5359. Its price to sales ratio in the trailing 12-months stood at 14.3102.
Nurix Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $350.62 million
- Total Liabilities
- $72.26 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $1.08 million
- Dividend Payout Ratio
- 0%
Nurix Therapeutics Inc ended 2024 with $350.62 million in total assets and $0 in total liabilities. Its intangible assets were valued at $350.62 million while shareholder equity stood at $259.92 million.
Nurix Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $72.26 million in other current liabilities, 48000.00 in common stock, $-466262000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $58.96 million and cash and short-term investments were $281.18 million. The company’s total short-term debt was $5,583,000 while long-term debt stood at $0.
Nurix Therapeutics Inc’s total current assets stands at $290.01 million while long-term investments were $27.46 million and short-term investments were $222.22 million. Its net receivables were $0 compared to accounts payable of $4.53 million and inventory worth $0.
In 2024, Nurix Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $1.08 million.
Comparatively, Nurix Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $9.15
- 52-Week High
- $16.81
- 52-Week Low
- $8.12
- Analyst Target Price
- $28.92
Nurix Therapeutics Inc stock is currently trading at $9.15 per share. It touched a 52-week high of $16.81 and a 52-week low of $16.81. Analysts tracking the stock have a 12-month average target price of $28.92.
Its 50-day moving average was $9.24 and 200-day moving average was $10.22 The short ratio stood at 19.93 indicating a short percent outstanding of 0%.
Around 318.2% of the company’s stock are held by insiders while 9274.6% are held by institutions.
Frequently Asked Questions About Nurix Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing DeTIL-0255, a drug-enhanced investigational cell therapy product that uses NX-0255 ex vivo to enhance tumor infiltrating lymphocytes propagation and phenotypic characteristics. The company has a strategic collaboration agreement with Gilead Sciences, Inc. to discover, develop, and commercialize a pipeline of protein degradation drugs for patients with cancer and other challenging diseases; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.